Drug Trial Radar · NCT04386070
Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
281
Actual
Start
May 16, 2022
Primary completion
Jun 30, 2023
Study completion Jun 30, 2023
Sponsor
- Lead sponsor
- University of BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Christian Medical College and Hospital, Ludhiana, India; Ministry of Health, Ghana; University of Lagos, Nigeria; Kigali University Teaching Hospital; Hospital Español Veracruz; Université d'Abomey-Calavi; University of Witwatersrand, South Africa; University of Edinburgh; Istituto Clinico Humanitas; University of Cape Town
- First posted
- May 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to reduce pulmonary complications in adult patients undergoing abdominal or thoracic surgery in COVID-19 exposed hospital environments. A Trial in Low and Middle Income Countries (LMICs)
Conditions
- Pulmonary Complications in Surgical Patients
- COVID
- Severe Acute Respiratory Syndrome
Interventions
RESP301Drug
RESP301 is a formulation consisting of three agents already used in clinical practice: mannitol, sodium nitrite and citric acid. Delivered by a vibrating mesh nebuliser three times per day (TID) (at least 4 hours apart), for 7 days. Each dose of RESP301 is a 6ml admixture of 150mM NaNO2, 50mM mannitol and 100mM citric acid, buffered at pH 5.4.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pneumonia free survival; acute respiratory distress syndrome (ARDS) free survival; or deathTime frame: From randomisation until discharge from hospital, average less than 30 days
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
University Of Abuja Teaching Hospital (Spoke)
Gwagwalada, Nigeria
Lagos University Teaching Hospital (Hub)
Lagos, Nigeria
Nnamdi Azikiwe University Teaching Hospital (Spoke)
Nnewi, Nigeria
University Teaching Hospital of Butare (CHUB) (Spoke)
Butare, Rwanda
Kibungo Referral Hospital (Spoke)
Kibungo, Rwanda
Kibagabaga Hospital (Spoke)
Kigali, Rwanda
University Teaching Hospital of Kigali (Hub)
Kigali, Rwanda
Kibogora District Hospital (Spoke)
Kirambo, Rwanda
Ruhengeri Referral Hospital (Spoke)
Ruhengeri, Rwanda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.